Literature DB >> 24944397

Combination therapy for chronic invasive rhinocerebral aspergillosis in a clinically immunocompetent patient.

László Lujber1, Imre Gerlinger2, Adám Kuncz3, József Pytel4.   

Abstract

BACKGROUND: Adequate therapy for chronic invasive rhinocerebral aspergillosis in immunocompetent patients is controversial. The incidence of the disease is high in the Sudan and the Middle East. Misinterpretation of diagnostic criteria, failure to verify tissue invasion of fungi, and a lack of understanding of the pathophysiology of various forms of fungal rhinosinusitis lead to controversies in nomenclature, diagnosis, and therapy.
OBJECTIVE: The aim of this report was to detail the clinical presentation and the endoscopic and imaging study findings of a patient with invasive Aspergillus rhinosinusitis with endocranial and orbital extension. This patient was treated with surgical débridement and a combination of antifungal drugs and immunomodulatory therapy.
METHODS: Endoscopic débridement and high-dose liposomal amphotericin B, in combination with flucytosine and immunomodulators, were used to treat this patient.
RESULTS: After treatment, the patient experienced 3 years of disease-free follow-up.
CONCLUSION: Surgical débridement and high-dose systemic combined antifungal therapy with immunomodulatory drugs produced an excellent long-term result for this apparently immunocompetent patient with extensive invasive fungal rhinosinusitis with cerebral and orbital involvement.

Entities:  

Keywords:  amphotericin B; aspergillosis; immunocompetent; invasive; rhinocerebral

Year:  2003        PMID: 24944397      PMCID: PMC4053017          DOI: 10.1016/S0011-393X(03)00111-5

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  24 in total

Review 1.  Definitions of fungal rhinosinusitis.

Authors:  B J Ferguson
Journal:  Otolaryngol Clin North Am       Date:  2000-04       Impact factor: 3.346

Review 2.  Issues in the management of invasive aspergillosis.

Authors:  D W Denning
Journal:  Ann Med Interne (Paris)       Date:  1995

3.  Transcranial resection of tumors of the paranasal sinuses and nasal cavity.

Authors:  J B Blacklock; R S Weber; Y Y Lee; H Goepfert
Journal:  J Neurosurg       Date:  1989-07       Impact factor: 5.115

4.  Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

Review 5.  Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery--case report and review of the literature.

Authors:  J M Coleman; G G Hogg; J V Rosenfeld; K D Waters
Journal:  Neurosurgery       Date:  1995-04       Impact factor: 4.654

6.  Aspergillosis of the paranasal sinuses x-ray diagnosis, histopathology, and clinical aspects.

Authors:  H Stammberger; R Jakse; F Beaufort
Journal:  Ann Otol Rhinol Laryngol       Date:  1984 May-Jun       Impact factor: 1.547

7.  Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections.

Authors:  A C Leenders; S Daenen; R L Jansen; W C Hop; B Lowenberg; P W Wijermans; J Cornelissen; R Herbrecht; H van der Lelie; H C Hoogsteden; H A Verbrugh; S de Marie
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

8.  Aggressive combined modality treatment of progressive sinonasal fungal infections in immunocompromised patients.

Authors:  P Goering; N T Berlinger; D J Weisdorf
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

9.  Rhinocerebral aspergillosis.

Authors:  M Kameswaran; A al-Wadei; P Khurana; B C Okafor
Journal:  J Laryngol Otol       Date:  1992-11       Impact factor: 1.469

10.  Chronic fungal sinusitis in apparently normal hosts.

Authors:  R G Washburn; D W Kennedy; M G Begley; D K Henderson; J E Bennett
Journal:  Medicine (Baltimore)       Date:  1988-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.